Menu

A+ A A-

Download article

DOI: https://doi.org/10.22263/2312-4156.2019.5.77

Volkava M.V.1, Kundzer E.V.1, Generalov I.I.2, Senkovich S.A.2, Kundzer V.I.3
Clinical value of blood serum enzymatic activity, proinflammatory cytokines and ferritin in rheumatoid arthritis
1Belarusian Medical Academy of Post-Graduate Education, Minsk, Republic of Belarus
2Vitebsk State Order of Peoples’ Friendship Medical University, Vitebsk, Republic of Belarus
3Lyceum of Belarusian State University, Minsk, Republic of Belarus

Vestnik VGMU. 2019;18(5):77-83.

Abstract.
The use of a wide range of biomarkers underlies the development of a personalized approach to the diagnosis and treatment of rheumatoid arthritis (RA). The aim of the work was to study the levels of enzymatic activity of blood serum, proinflammatory cytokines, ferritin in RA and to determine their clinical value.
The study included 128 patients with a reliable diagnosis of RA according to the criteria of EULAR / ACR 2010, as well as 33 healthy volunteers. The levels of DNAse and hyaluronidase activity of blood serum, tumor necrosis factor alpha (TNF-α), interleukin -6 (IL-6), interleukin 17A (IL-17A), ferritin were determined.
Blood serum enzymatic activity, IL-6, IL-17A and ferritin levels in RA patients were significantly higher than  those in the control group (p<0.05). TNF-α level in RA patients did not exceed the control values. The levels of serum enzymatic activity, proinflammatory cytokines and ferritin were compared with clinical, laboratory and instrumental characteristics of RA, as a result, a number of relationships were found that indicate the possibility of using the studied parameters as biomarkers in RA.
Key words: rheumatoid arthritis, DNAse serum activity, hyaluronidase serum activity, cytokines, ferritin.

References

1. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010 Sep;62(9):2569-81. doi: http://dx.doi.org/10.1002/art.27584
2. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011 Dec;365(23):2205-19. doi: http://dx.doi.org/10.1056/NEJMra1004965
3. Schett G, Gravallese E. Bone erosion in rheumatoid arthritis: mechanisms, diagnosis and treatment. Nat Rev Rheumatol. 2012 Nov;8(11):656-64. doi: http://dx.doi.org/10.1038/nrrheum.2012.153
4. Choy E. Understanding the dynamics: pathways involved in the pathogenesis of rheumatoid arthritis. Rheumatology (Oxford). 2012 Jul;51 Suppl 5:v3-11. doi: http://dx.doi.org/10.1093/rheumatology/kes113
5. Volkova MV, Kunder EV. Differential criteria for the diagnosis of early arthritis based on the assessment of serum hyaluronidase and deoxyribonuclease activity. Klin Lab Diagnostika. 2012;(10):22-6. (In Russ.)
6. Xu XY, Yang WF, Zhang SG, Zhao Q, Linag LJ, Wang X, Shen HL. Correlation of DNase I in serum and synovial fluid with inflammatory activity in patients with rheumatoid arthritis. Nan Fang Yi Ke Da Xue Xue Bao. 2016 Aug;36(9):1204-8.
7. Yeo L, Toellner KM, Salmon M, Filer A, Buckley CD, Raza K, et al. Cytokine mRNA profiling identifies B cells as a major source of RANKL in rheumatoid arthritis. Ann Rheum Dis. 2011 Nov;70(11):2022-8. doi: http://dx.doi.org/10.1136/ard.2011.153312
8. Moelants EA, Mortier A, Van Damme J, Proost P. Regulation of TNF-alpha with a focus on rheumatoid arthritis. Immunol Cell Biol. 2013 Jul;91(6):393-401. doi: http://dx.doi.org/10.1038/icb.2013.15
9. Lee SJ, Lee A, Hwang SR, Park JS, Jang J, Huh MS, et al. TNF-alpha gene silencing using polymerized siRNA/thiolated glycol chitosan nanoparticles for rheumatoid arthritis. Mol Ther. 2014 Feb;22(2):397-408. doi: http://dx.doi.org/10.1038/mt.2013.245
10. Boissier MC. Cell and cytokine imbalances in rheumatoid synovitis. Joint Bone Spine. 2011 May;78(3):230-4. doi: http://dx.doi.org/10.1016/j.jbspin.2010.08.017
11. Nishimoto N, Kishimoto T. Interleukin 6: from bench to bedside. Nat Clin Pract Rheumatol. 2006 Nov;2(11):619-26. doi: http://dx.doi.org/10.1038/ncprheum0338
12. Foster W, Carruthers D, Lip GY, Blann AD. Inflammatory cytokines, endothelial markers and adhesion molecules in rheumatoid arthritis: effect of intensive anti-inflammatory treatment. J Thromb Thrombolysis. 2010 May;29(4):437-42. doi: http://dx.doi.org/10.1007/s11239-009-0370-y
13. Gullick NJ, Abozaid HS, Jayaraj DM, Evans HG, Scott DL, Choy EH, et al. Enhanced and persistent levels of interleukin (IL)-17(+) CD4(+) T cells and serum IL-17 in patients with early inflammatory arthritis. Clin Exp Immunol. 2013 Nov;174(2):292-301. doi: http://dx.doi.org/10.1111/cei.12167
14. Przybyszewska J, Żekanowska E, Kędziora-Kornatowska K, Boinska J, Cichon R, Porzych K. Serum prohepcidin and other iron metabolism parameters in elderly patients with anemia of chronic disease and with iron defciency anemia. Pol Arch Med Wewn. 2013;123(3):105-11.
15. Azarenok KS, Generalov II, Golubeva AG, Zheleznyak NV, Konorev MR; Viteb med in-t, zaiavitel' i patentoobladatel'. Method for determining DNase activity: pat 1066 Resp Belarus': MPK S 12 Q 1/34, S 12 N 9/22. № 243A; zaiavl 06.04.93; opubl 14.03.96. (In Russ.)
16. Azarenok KS, Generalov II. Determination of hyaluronidase activity by the rivanol clot method. Klin Lab Diagnostika. 1994;(5):40-2. (In Russ.)
17. Nagata S. Rheumatoid polyarthritis caused by a defectin in DNA degradation. Cytokine Growth Factor Rev. 2008 Jun-Aug;19(3-4):295-302. doi: http://dx.doi.org/10.1016/j.cytogfr.2008.04.009
18. Nijenhuis S, Zendman AJ, Vossenaar ER, Pruijn GJ, vanVenrooij WJ. Autoantibodies to citrullinated proteins in rheumatoid arthritis: clinical performance and biochemical aspects of an RA-specific marker. Clin Chim Acta. 2004 Dec;350(1-2):17-34. doi: http://dx.doi.org/10.1016/j.cccn.2004.07.016
19. Shimamoto K, Ito T, Ozaki Y, Amuro H, Tanaka A, Nishizawa T, et al. Serum interleukin 6 before and after therapy with tocilisumab is a principal biomarker in patients with rheumatoid arthritis. J Rheumatol. 2013 Jul;40(7):1074-81. doi: http://dx.doi.org/10.3899/jrheum.121389
20. Diaz-Torne C, Ortiz MDA, Moya P, Hernandez MV, Reina D, Castellvi I, et al. The combination of IL-6 and its soluble receptor is associated with the response of rheumatoid arthritis patients to tocilisumab. Semin Arthritis Rheum. 2018 Jun;47(6):757-764. doi: http://dx.doi.org/10.1016/j.semarthrit.2017.10.022
21. Seyhan S, Pamuk ÖN, Pamuk GE, Çakır N. The correlation berween ferritin level and acute phase parameters in rheumatoid arthritis and systemic lupus erythematosus. Eur J Rheumatol. 2014 Sep;1(3):92-95. doi: http://dx.doi.org/10.5152/eurjrheumatol.2014.032

Information about authors:
Volkava M.V. – Candidate of Medical Sciences, doctoral candidate of the Chair of Cardiology & Rheumatology, Belarusian Medical Academy of Post-Graduate Education,
ORCID: https://orcid.org/0000-0001-8572-9252;
Kundzer E.V. – Doctor of Medical Sciences, professor of the Chair of Cardiology & Rheumatology, Belarusian Medical Academy of Post-Graduate Education;
Generalov I.I. – Doctor of Medical Sciences, professor of the Chair of Clinical Microbiology, Vitebsk State Order of Peoples’ Friendship Medical University;
Senkovich S.A. – Candidate of Medical Sciences, associate professor of the Chair of Clinical Microbiology, Vitebsk State Order of Peoples’ Friendship Medical University;
Kundzer V.I. – student, Lyceum of Belarusian State University.

Correspondence address: Republic of Belarus, 220013, Minsk, 64 Nezavisimosti ave., Belarusian Medical Academy of Post-Graduate Education, Chair of Cardiology & Rheumatology. E-mail: Этот адрес электронной почты защищён от спам-ботов. У вас должен быть включен JavaScript для просмотра. – Margaryta V. Volkava.

Поиск по сайту